VJOncology is committed to improving our service to you

ASCO 2020 | Mesothelioma data at ASCO 2020

VJOncology is committed to improving our service to you

Riyaz Shah

Riyaz Shah, FRCP, PhD, Maidstone and Tunbridge Wells NHS Trust, Kent, UK, highlights data coming from the RAMES study (NCT03560973) which evaluated the addition of ramucirumab, a VEGFR2 inhibitor, to gemcitabine in patients with relapsed, advanced mesothelioma. Dr Shah also highlights data coming from other recent studies in mesothelioma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter